3B Blackbio DX Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹1,112 Cr
- P/E
- 20.04
- ROE
- 19.77%
- PEG
- 0.62
- Price to sales
- 7.26
- Debt to equity
- 0.01
- 52W high / low
- ₹1,710 / ₹1,103
- Sales growth (5Y)
- -8.95%
- EBITDA margin
- 34.90%
- Net profit margin
- 42.23%
- Promoter holding
- 40.95%
- Sales (last year)
- ₹153 Cr
Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products[1]
Guidance scorecard · Q1 FY27 call
What 3B Blackbio DX Ltd's management guided
and where it ranks in Healthcare Services
Healthcare Services
RevenueQ4 FY26 call
10–20%- The company targets a revenue growth of 15% to 20% for FY27 and onward.
- Coris is expected to contribute around INR50 crores in topline, growing slightly with EBITDA turning slightly positive in FY27, targeting 5%-10% EBITDA margin by FY28.
- The overall consolidated topline for FY27 is expected to be INR175-180 crores.
- The Indian domestic market is expected to grow around 15%, with international operations growing 20%-25%, leading to consolidated growth of 15%-20%.
- Competition from China affects a small product segment.
2 more points from 3B Blackbio DX Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ4 FY26 call
See what 3B Blackbio DX Ltd said on margins — free account, 30 seconds.
CapexQ4 FY26 call
Planned- The company is well-positioned for expansion, currently utilizing around 50% of its capacity.
- Expected capex for capacity expansion is relatively low, approximately INR 4-5 crores.
- Free cash flow generation is strong, about INR 40 crores plus annually, leading to a significant cash balance available for investments.
- There is a clear focus on inorganic growth through M&A, with multiple consultants appointed in France, UK, and US to scout opportunities.
- M&A targets typically have a minimum topline of EUR 2 million, preferably EBITDA positive or turnaround candidates.
- The company aims to keep a cash reserve of INR 50 crores specifically for M&A deals.
2 more points from 3B Blackbio DX Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ4 FY26 call
None plannedSee what 3B Blackbio DX Ltd said on fundraising — free account, 30 seconds.
Order bookQ4 FY26 call
- Coris contract initially was Euro 6 million for four years starting 2024.
- Out of Euro 6 million, approximately Euro 3.45 million has been executed (2.1 million + 1.35 million).
- Around Euro 2.4 million remains to be executed through FY28.
- The Coris HAT order is expected to remain broadly similar in the current year.
- Exact timing of order execution can be affected by external factors like Ebola outbreak in Congo, causing possible delays.
- For FY27, Coris is expected to be around INR 50 crores in revenue with EBITDA roughly flat or slightly positive.
2 more points from 3B Blackbio DX Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Healthcare Services companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹903 Cr | — | |
| 2 | 40%+ | Flat | ₹583 Cr | 22.2 | |
| 3 | Aster DM Quality Care Ltd | 20–40% | Up 2%+ | ₹58,782 Cr | 162.9 |
| 4 | 20–40% | Up 0–2% | ₹1,730 Cr | 17.5 | |
| 5 | 20–40% | Up 0–2% | ₹580 Cr | 11.9 | |
| 6 | 20–40% | Flat | ₹1.13L Cr | 53.9 |
Sign up free to see every company in the sector ranking and track 3B Blackbio DX Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Healthcare Services rankingFinancials of 3B Blackbio DX Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of 3B Blackbio DX Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 15 | 18 | 14 | 19 | 18 | 23 | 19 | 29 | 25 | 22 | 22 | 34 | 50 |
| Expenses + | 7 | 11 | 8 | 11 | 9 | 13 | 8 | 13 | 10 | 15 | 10 | 19 | 29 |
| Operating Profit | 7 | 7 | 6 | 8 | 9 | 10 | 11 | 16 | 15 | 8 | 12 | 15 | 22 |
| OPM % | 50% | 41% | 45% | 41% | 50% | 43% | 56% | 55% | 59% | 35% | 53% | 43% | 43% |
| Other Income + | 3 | 1 | 3 | 3 | 3 | 4 | 4 | 3 | 3 | 5 | 4 | 6 | 6 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Profit before tax | 10 | 8 | 9 | 10 | 11 | 14 | 14 | 19 | 18 | 13 | 16 | 20 | 27 |
| Tax % | 22% | 38% | 22% | 26% | 24% | 36% | 21% | 23% | 24% | 36% | 20% | 23% | 16% |
| Net Profit + | 8 | 5 | 7 | 8 | 9 | 9 | 11 | 15 | 13 | 8 | 13 | 15 | 22 |
| EPS in Rs | 8.96 | 7.72 | 9.71 | 10.46 | 10.16 | 10.33 | 12.97 | 17.07 | 15.61 | 9.79 | 14.67 | 17.14 | 25.32 |
Financials of 3B Blackbio DX Ltd
Profit & Loss
Annual income statement trend
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 22 | 19 | 17 | 16 | 23 | 23 | 29 | 227 | 81 | 62 | 74 | 96 | 129 |
| Expenses + | 21 | 18 | 16 | 14 | 18 | 16 | 20 | 77 | 44 | 33 | 41 | 46 | 73 |
| Operating Profit | 1 | 1 | 2 | 3 | 5 | 7 | 9 | 150 | 37 | 29 | 33 | 50 | 56 |
| OPM % | 6% | 7% | 9% | 16% | 23% | 31% | 32% | 66% | 46% | 47% | 44% | 52% | 44% |
| Other Income + | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 7 | 7 | 13 | 15 | 20 |
| Interest | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Profit before tax | 0 | 0 | 0 | 1 | 5 | 7 | 10 | 152 | 43 | 35 | 44 | 64 | 75 |
| Tax % | 14% | 23% | 23% | 19% | 24% | 25% | 23% | 25% | 26% | 27% | 28% | 25% | |
| Net Profit + | 0 | 0 | 0 | 1 | 3 | 5 | 8 | 114 | 32 | 26 | 32 | 48 | 58 |
| EPS in Rs | 0.59 | 0.36 | 0.51 | 1.76 | 5.35 | 8.18 | 10.24 | 151.66 | 42.89 | 34.55 | 37.40 | 55.57 | 66.92 |
| Dividend Payout % | 0% | 0% | 0% | 17% | 9% | 6% | 7% | 6% | 24% | 8% | 8% | 7% |
Financials of 3B Blackbio DX Ltd
Balance Sheet
Capital structure and asset base
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 9 | 9 | 9 | 9 |
| Reserves | 4 | 4 | 4 | 5 | 12 | 16 | 25 | 125 | 146 | 185 | 214 | 260 | 290 |
| Borrowings + | 7 | 8 | 8 | 9 | 6 | 6 | 4 | 2 | 3 | 2 | 1 | 0 | 0 |
| Other Liabilities + | 7 | 7 | 6 | 6 | 6 | 8 | 9 | 59 | 37 | 19 | 24 | 27 | 42 |
| Total Liabilities | 24 | 25 | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 296 | 341 |
| Fixed Assets + | 4 | 4 | 3 | 3 | 4 | 4 | 4 | 5 | 7 | 8 | 7 | 7 | 17 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 59 | 93 | 92 | 117 | 156 | 160 |
| Other Assets + | 20 | 21 | 21 | 22 | 26 | 32 | 40 | 130 | 93 | 114 | 123 | 132 | 163 |
| Total Assets | 24 | 25 | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 296 | 341 |
Financials of 3B Blackbio DX Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 0 | 0 | 1 | 1 | 2 | 4 | 7 | 98 | 37 | 20 | 27 | 43 |
| Cash from Investing Activity + | -0 | -0 | -0 | -0 | -1 | -1 | -1 | -70 | -28 | 15 | -20 | -33 |
| Cash from Financing Activity + | 0 | -0 | -1 | -0 | 0 | -1 | 1 | -2 | -15 | -5 | -4 | -3 |
| Net Cash Flow | 0 | -0 | 0 | 0 | 1 | 2 | 7 | 26 | -6 | 30 | 3 | 7 |
| Free Cash Flow | -0 | 0 | 1 | 0 | 1 | 3 | 6 | 96 | 35 | 18 | 26 | 42 |
| CFO/OP | 25% | 23% | 69% | 36% | 52% | 71% | 101% | 90% | 129% | 100% | 115% | 116% |
Financials of 3B Blackbio DX Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 213 | 262 | 283 | 321 | 259 | 290 | 252 | 56 | 136 | 200 | 179 | 138 |
| Inventory Days | 120 | 145 | 143 | 175 | 164 | 141 | 124 | |||||
| Days Payable | 189 | 218 | 203 | 186 | 69 | 66 | 28 | |||||
| Cash Conversion Cycle | 144 | 188 | 223 | 310 | 259 | 290 | 252 | 56 | 136 | 296 | 253 | 235 |
| Working Capital Days | 144 | 175 | 205 | 247 | 253 | 287 | 275 | 65 | 162 | 241 | 215 | 169 |
| ROCE % | 7% | 7% | 7% | 13% | 24% | 28% | 31% | 162% | 27% | 19% | 21% | 26% |
Guidance history
How 3B Blackbio DX Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q4 FY26 call → | 10–20% | — | Planned | None planned | — |
| Q3 FY26 call → | 10–20% | Flat | Planned | — | — |
| Q1 FY26 call → | 20–40% | — | Planned | None planned | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
32 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | −3.7% | 57% |
| Last 6 months | +8.0% | 66% |
| Last 3 months | +3.9% | 74% |
The price is 38.2% below its all-time high of ₹2,097.45 (13 Dec 2024). Stocks more than 20% below their peak have their score halved, so 64 became 32.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For 3B Blackbio DX Ltd: 0.4 × 57 + 0.4 × 66 + 0.2 × 74 = 64, halved to 32 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 30 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What 3B Blackbio DX Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Rainbow Childrens Medicare Ltd (Q2 FY27)
Year-on-year (YoY) growth in revenue: 23.2% . Key investor presentation takeaways from Rainbow Childrens Medicare Ltd's Q2 FY27 investor presentation — and how
- Narayana Hrudayalaya Ltd (Q2 FY27)
Consolidated operating revenue for Q2 FY27: ₹28,440 Mn, up 73.0% YoY (Page 15, 16). Key investor presentation takeaways from Narayana Hrudayalaya Ltd's Q2 FY27
- Artemis Medicare Services Ltd (Q2 FY27)
Q2 FY27 consolidated revenue from operations: INR 31,104 Lacs, up 13.2% YoY (Page 39, 40, 20). Key investor presentation takeaways from Artemis Medicare Service
- Max Healthcare Institute Ltd (Q2 FY27)
Q2 FY27 Gross Revenue: ₹3,219 Cr, up 20% YoY (Page 4, 17) . Key investor presentation takeaways from Max Healthcare Institute Ltd's Q2 FY27 investor presentatio